<DOC>
	<DOCNO>NCT00786851</DOCNO>
	<brief_summary>This prospective , multicenter phase II trial design evaluate safety activity combination Lenalidomide ( Len ) Dexamethasone ( Dex ) patient relapsed/refractory mantle cell lymphoma ( MCL ) .</brief_summary>
	<brief_title>Salvage Treatment With Lenalidomide Dexamethaosne ( LEN-DEX ) Patients With Relapsed/Refractory Mantle Cell Lymphoma ( MCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis MCL Understand voluntarily sign informed consent form ; Able adhere study visit schedule protocol requirement ; Age ≥ 18 ; Patients treat least one prior treatment regimen , eligible relapse intensive treatment ( stem cell transplant ) ; Patients refractory relapse disease ; Measurable and/or valuable disease ; Adequate haematological count : ANC &gt; 1.5 x 109/L platelet count &gt; 75 x 109/L unless due bone marrow involvement MCL ; Conjugated bilirubin 2 x ULN unless due liver involvement MCL ; Alkaline phosphatase transaminases 2 x ULN unless due liver involvement MCL ; Creatinine clearance ≥ 50 ml/min ; HIV negativity ; HCV negativity ; HBV negativity patient HBcAb + , HbsAg , HBs Ab+/ anti HBV prophylaxis lamivudine ; Non peripheral neuropathy CNS disease ; Life expectancy &gt; 6 month ; Performance status &lt; 2 accord ECOG scale ; Disease free prior malignancy ( part MCL ) exception currently treat basal cell , squamous cell carcinoma skin , carcinoma `` situ '' cervix breast ; Written inform consent ; Females childbearing potential ( FCBP ) must agree use two reliable form contraception simultaneously practice complete abstinence heterosexual intercourse follow time period relate study : 1 ) least 28 day start study drug ; 2 ) participate study ; 3 ) least 28 day discontinuation study . The two method reliable contraception must include one highly effective method ( i.e . intrauterine device ( IUD ) , hormonal [ birth control pill , injection , implant ] , tubal ligation , partner 's vasectomy ) one additional effective ( barrier ) method ( i.e . latex condom , diaphragm , cervical cap ) . FCBP must refer qualified provider contraceptive method need ; Patients receive experimental drug use experimental medical device within 4 week plan start treatment . Concurrent participation nontreatment study allow , interfere participation study ; CNS disease ( meningeal and/or brain involvement lymphoma ) ; TVP last year ; History clinically relevant liver renal insufficiency ; significant cardiac , vascular , pulmonary , gastrointestinal , endocrine , neurologic , rheumatologic , hematologic , psychiatric , metabolic disturbance ; Uncontrolled diabetes ( receive antidiabetic agent , subject must stable dose least 3 month first dose study drug ) ; Creatinine clearances &lt; 50 ml/min ; HIV positivity ; HBV positivity exception patient HBVcAb + , HbsAg , HBs Ab+/ anti HBV prophilaxis lamivudine ; Pregnant lactate woman ; Hypersensitivity reactions previous thalidomide ( ) ; Prior rash ≥ 3 take thalidomide ( ) ; Active opportunistic infection ; Any coexist medical psychological condition would preclude participation study compromise ability give inform consent ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>MANTLE CELL LYMPHOMA ( MCL )</keyword>
	<keyword>Lenalidomide ( Len )</keyword>
	<keyword>Dexamethasone ( Dex )</keyword>
</DOC>